Novo Nordisk and Evotec collaborate to launch LAB eN², a translational drug discovery accelerator, to address innovation gap in cardiometabolic diseases

[ad_1] LAB eN² will involve institutions including Harvard University, Mass General Brigham, and Beth Israel Deaconess Medical Center Focus of the collaboration is to accelerate the translation of academic ideas…